Shares of Epizyme Inc. (NASDAQ:EPZM) shot up 7.8% on Friday . The company traded as high as $10.62 and last traded at $10.60, with a volume of 264,065 shares changing hands. The stock had previously closed at $9.83.

A number of brokerages have recently weighed in on EPZM. Leerink Swann restated a “buy” rating on shares of Epizyme in a research note on Tuesday, April 19th. HC Wainwright restated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Cowen and Company restated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Mizuho restated a “buy” rating and issued a $18.00 target price on shares of Epizyme in a research note on Monday, June 20th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $26.00 target price on shares of Epizyme in a research note on Monday, June 20th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $23.11.

The company has a 50 day moving average price of $10.19 and a 200 day moving average price of $10.49. The stock’s market capitalization is $590.53 million.

Epizyme (NASDAQ:EPZM) last released its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.12. Equities research analysts anticipate that Epizyme Inc. will post ($2.25) EPS for the current year.

In other news, insider Robert A. Copeland sold 4,000 shares of the company’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the sale, the insider now directly owns 35,538 shares in the company, valued at approximately $368,529.06. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

A hedge fund recently bought a new stake in Epizyme stock. California Public Employees Retirement System bought a new position in shares of Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned 0.41% of Epizyme at the end of the most recent quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.